These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9272186)

  • 1. Biologically active TGF-beta 1 is increased in cerebrospinal fluid while it is reduced in serum in multiple sclerosis patients.
    Rollnik JD; Sindern E; Schweppe C; Malin JP
    Acta Neurol Scand; 1997 Aug; 96(2):101-5. PubMed ID: 9272186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible role of transforming growth factor-beta in relapsing-remitting multiple sclerosis.
    Carrieri PB; Provitera V; Bruno R; Perrella M; Tartaglia G; Busto A; Perrella O
    Neurol Res; 1997 Dec; 19(6):599-600. PubMed ID: 9427959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of IFN-gamma, IL-4, and TGF-beta in multiple sclerosis in relation to HLA-Dw2 phenotype and stage of disease.
    Söderström M; Hillert J; Link J; Navikas V; Fredrikson S; Link H
    Mult Scler; 1995 Nov; 1(3):173-80. PubMed ID: 9345450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
    Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
    PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transferrin in patients with multiple sclerosis: a comparison among various subgroups of multiple sclerosis patients.
    Zeman D; Adam P; Kalistová H; Sobek O; Kelbich P; Andel J; Andel M
    Acta Neurol Scand; 2000 Feb; 101(2):89-94. PubMed ID: 10685854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
    Link J
    Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The alterations of cerebrospinal fluid TNF-alpha and TGF-beta2 levels in early relapsing-remitting multiple sclerosis.
    Grzegorski T; Iwanowski P; Kozubski W; Losy J
    Immunol Res; 2022 Oct; 70(5):708-713. PubMed ID: 35729473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis.
    Horellou P; Wang M; Keo V; Chrétien P; Serguera C; Waters P; Deiva K
    J Neuroimmunol; 2015 Dec; 289():1-7. PubMed ID: 26616865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming growth factor-Beta 1 (tgf-Beta 1) in patients with amyotrophic lateral sclerosis.
    Iłzecka J; Stelmasiak Z; Dobosz B
    Cytokine; 2002 Dec; 20(5):239-43. PubMed ID: 12550109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity.
    Carrieri PB; Provitera V; De Rosa T; Tartaglia G; Gorga F; Perrella O
    Immunopharmacol Immunotoxicol; 1998 Aug; 20(3):373-82. PubMed ID: 9736442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study.
    Wurth S; Kuenz B; Bsteh G; Ehling R; Di Pauli F; Hegen H; Auer M; Gredler V; Deisenhammer F; Reindl M; Berger T
    PLoS One; 2017; 12(8):e0182462. PubMed ID: 28777826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.
    Mouzaki A; Rodi M; Dimisianos N; Emmanuil A; Kalavrizioti D; Lagoudaki R; Grigoriadis NC; Papathanasopoulos P
    PLoS One; 2015; 10(8):e0135434. PubMed ID: 26317430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis.
    Rentzos M; Cambouri C; Rombos A; Nikolaou C; Anagnostouli M; Tsoutsou A; Dimitrakopoulos A; Triantafyllou N; Vassilopoulos D
    J Neurol Sci; 2006 Feb; 241(1-2):25-9. PubMed ID: 16316662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b).
    Nicoletti F; Di Marco R; Patti F; Reggio E; Nicoletti A; Zaccone P; Stivala F; Meroni PL; Reggio A
    Clin Exp Immunol; 1998 Jul; 113(1):96-9. PubMed ID: 9697990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to the axolemma-enriched fraction in the cerebrospinal fluid and serum of patients with multiple sclerosis and other neurological diseases.
    Rawes JA; Calabrese VP; Khan OA; DeVries GH
    Mult Scler; 1997 Dec; 3(6):363-9. PubMed ID: 9493635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of serum levels of orexin-A, transforming growth factor β, and leptin in patients with multiple sclerosis.
    Moharami S; Nourazarian A; Nikanfar M; Laghousi D; Shademan B; Joodi Khanghah O; Khaki-Khatibi F
    J Clin Lab Anal; 2022 Jan; 36(1):e24170. PubMed ID: 34894407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with Rapamycin.
    Salehi M; Bagherpour B; Shayghannejad V; Mohebi F; Jafari R
    Iran J Immunol; 2016 Jun; 13(2):141-7. PubMed ID: 27350635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential role of transforming growth factor-beta 1 in terminating the immune response in patients with Guillain-Barré syndrome.
    Sindern E; Schweppe K; Ossege LM; Malin JP
    J Neurol; 1996 Mar; 243(3):264-8. PubMed ID: 8936357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease.
    Signoriello E; Mallardo M; Nigro E; Polito R; Casertano S; Di Pietro A; Coletta M; Monaco ML; Rossi F; Lus G; Daniele A
    Mol Neurobiol; 2021 Jun; 58(6):2663-2670. PubMed ID: 33486671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
    Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
    Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.